KRAS and colorectal neoplasm: Profiling colorectal tumours for wild type versus mutated KRAS gene has been valuable for selecting patients who are unlikely to benefit with cetuximab or panitumumab [44], [45], [46]; however, these KRAS mutations are uncommon in HNSCC [47], [48].